A Single-Arm, Open-Label, Pilot Study and Expansion Study of JAK Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Latest Information Update: 09 Apr 2025
At a glance
- Drugs Itacitinib (Primary)
- Indications Cytokine release syndrome; Graft-versus-host disease
- Focus Therapeutic Use
Most Recent Events
- 28 Jun 2024 Status changed from active, no longer recruiting to completed.
- 11 Mar 2024 Planned End Date changed from 13 Sep 2024 to 5 Sep 2024.
- 11 Mar 2024 Planned primary completion date changed from 22 Jun 2024 to 17 Jun 2024.